Oncotelic Therapeutics (OTCQB: OTLC) will take a prominent stage at the 22nd Drug Discovery Strategic Summit, where Chief Business Officer Saran Saund is set to deliver the opening keynote on October 22, 2026, at 9 a.m. Pacific Time in Millbrae, California. The presentation will center on partition and aggregation as an organizing principle for artificial intelligence in drug discovery, a framework that could reshape how research teams approach complex biological questions.
Saund will explain how breaking large research problems into smaller, focused investigations and then combining the findings can yield testable hypotheses more efficiently. This methodology underpins Oncotelic’s proprietary PDAOAI platform, which indexes approximately 29 million PubMed abstracts. By structuring AI-driven analysis around partition and aggregation, the company aims to make AI-powered research accessible to individual investigators, not just large pharmaceutical teams, through planned technologies such as Fastbot and Membot.
The keynote matters because it signals Oncotelic’s push to position its AI platform as a core part of its drug discovery and development strategy, particularly for cancers with substantial unmet needs and rare pediatric indications. The company also plans to expand into genetic discovery and is pursuing an international intellectual property strategy around these tools. For investors, the presentation offers a public window into how Oncotelic intends to differentiate itself in the crowded AI drug discovery space. Full details are available in the complete press release.
Oncotelic develops oncology and immunotherapy products and has built the PDAOAI platform to support its internal research. The company’s newsroom, accessible via the latest OTLC updates, provides ongoing disclosures for investors tracking its progress.
The announcement was distributed through NetworkNewsWire, a communications platform focused on financial news and content distribution. NetworkNewsWire operates within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. The platform also offers corporate communications solutions tailored to public and private companies. Terms of use and disclaimers are available on the NetworkNewsWire disclaimer page.
The implications of Saund’s keynote extend beyond a single presentation. If partition and aggregation prove effective for organizing AI-driven drug discovery, Oncotelic could lower the barrier for individual researchers to leverage massive literature databases, potentially accelerating hypothesis generation in areas like rare pediatric cancers where resources are scarce. The planned expansion into genetic discovery further suggests the company is building a broader data-driven ecosystem around its platform. However, the approach remains to be validated, and the keynote will be watched for concrete evidence of how PDAOAI translates into actionable drug candidates.
